You are here: Home » PTI Stories » National » News
Business Standard

'Protein behind cancer spread identified'

Topics
Health Medical Pharma

Press Trust of India  |  Toronto 

Scientists, including one of Indian origin, have found that blocking a protein slows down cancer cell growth, an advance that may help develop a drug to treat the disease.

A study, published in the journal Nature Communications, identified the protein called NUAK2, which is produced by cancer cells to boost their proliferation and whose presence in tumours is associated with poor disease prognosis.

"We looked at bladder cancer and found that a subset of patients have high levels of NUAK2 protein in their tumours which also happened to be high-grade tumours," said Liliana Attisano, a professor at the University of Toronto in Canada.

Mandeep Gill, a graduate student in Attisano's lab, first found NUAK2 while looking for a way to block the known cancer-promoting proteins called YAP and TAZ (YAP/TAZ).

Highly active in many cancers, YAP/TAZ work by latching onto the DNA to switch on genes that promote cell proliferation.

NUAK2 turned out to be one of the genes that was switched on by YAP/TAZ.

It was found to encode a protein that helps shuttle even more YAP/TAZ into the cell's nucleus, where the DNA is stored, to further bolster abnormal cell growth.

Since YAP/TAZ are active in many cancers, including the aggressive forms of breast and bladder cancer, the researchers wondered if NUAK2 too was elevated in tumour biopsies taken from patients with bladder cancer.

They found that NUAK2 was present at high levels in some of the tumours and that those came from patients whose cancer progressed to a more aggressive type.

The flip side is that when NUAK2 is blocked, YAP/TAZ can no longer enter the nucleus, researchers said.

This keeps YAP/TAZ away from the DNA and breaks the vicious cycle by which cancer reinforces itself, they said.

YAP/TAZ belong to the so-called Hippo pathway, a network of proteins that are important for normal cell and tissue growth but which often goes haywire in cancer.

The pathway was named after its role in controlling organ size so that organs grow abnormally large, or "hippo-like", when the pathway breaks down.

Although the Hippo pathway, which normally keeps cell proliferation in check, is inactivated in many cancers, so far there was no good way to target it with drugs. The discovery of NUAK2 changes this, researchers said.

By blocking NUAK2 protein, either by drugs or by muting the gene that encodes it, the researchers were able to slow down expansion of breast cancer cells in the dish and to shrink breast tumours in mice, respectively.

A similar approach could target high-grade tumours in patients.

"If you check the patient's tumour and if they have high levels of NUAK2 protein, we could maybe treat them with NUAK2 inhibitors," researchers said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, August 29 2018. 17:45 IST
RECOMMENDED FOR YOU